You are here

  • Home
  • Archive
  • Volume 21, Issue 6
  • Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding

Article Text

Article menu
Download PDFPDF
Therapeutics/Prevention
Systematic review with meta analysis
Aspirin reduces cardiovascular events in primary prevention of cardiovascular disease but at a near equivalent risk of increased bleeding
  1. Michael D Miedema1,
  2. Salim S Virani2
  1. 1Minneapolis Heart Institute, Minneapolis, Minnesota, USA
  2. 2Michael E. DeBakey Veterans Affairs Medical Center and Baylor College of Medicine, Houston, Texas, USA
  1. Correspondence to : Professor Salim S Virani, Health Services Research and Development (152), 2002 Holcombe Boulevard, Houston, TX 77030, USA; virani{at}bcm.edu

https://doi.org/10.1136/ebmed-2016-110531

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the US Preventive Services Task Force. Ann Intern Med 2016;164:804–13OpenUrlCrossRefPubMed.

    Context

    The use of aspirin in primary prevention of cardiovascular disease (CVD) remains controversial, as randomised controlled trials (RCTs) have produced mixed results. Recently, the United States Preventive Services Task Force (USPSTF) published updated recommendations on the use of aspirin for primary prevention of CVD and colorectal cancer.1 This systematic review and meta-analysis served as the basis for these USPSTF recommendations for primary CVD prevention.

    Methods

    All trials from the previous 2009 USPSTF guideline on the use of aspirin for primary CVD prevention (minimum of 75 mg every other day for 1 year or more) in adults aged 40 or more were included, and a comprehensive literature search for additional trials from January 2008 to …

    View Full Text

    Footnotes

    • Competing interests None declared.

    • Provenance and peer review Commissioned; internally peer reviewed.